Cargando…

Overestimation of grey matter atrophy in glioblastoma patients following radio(chemo)therapy

OBJECTIVE: Brain atrophy has the potential to become a biomarker for severity of radiation-induced side-effects. Particularly brain tumour patients can show great MRI signal changes over time caused by e.g. oedema, tumour progress or necrosis. The goal of this study was to investigate if such change...

Descripción completa

Detalles Bibliográficos
Autores principales: Gommlich, A., Raschke, F., Petr, J., Seidlitz, A., Jentsch, C., Platzek, I., van den Hoff, J., Kotzerke, J., Beuthien-Baumann, B., Baumann, M., Krause, M., Troost, E. G. C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8901471/
https://www.ncbi.nlm.nih.gov/pubmed/33786695
http://dx.doi.org/10.1007/s10334-021-00922-3
_version_ 1784664374922706944
author Gommlich, A.
Raschke, F.
Petr, J.
Seidlitz, A.
Jentsch, C.
Platzek, I.
van den Hoff, J.
Kotzerke, J.
Beuthien-Baumann, B.
Baumann, M.
Krause, M.
Troost, E. G. C.
author_facet Gommlich, A.
Raschke, F.
Petr, J.
Seidlitz, A.
Jentsch, C.
Platzek, I.
van den Hoff, J.
Kotzerke, J.
Beuthien-Baumann, B.
Baumann, M.
Krause, M.
Troost, E. G. C.
author_sort Gommlich, A.
collection PubMed
description OBJECTIVE: Brain atrophy has the potential to become a biomarker for severity of radiation-induced side-effects. Particularly brain tumour patients can show great MRI signal changes over time caused by e.g. oedema, tumour progress or necrosis. The goal of this study was to investigate if such changes affect the segmentation accuracy of normal appearing brain and thus influence longitudinal volumetric measurements. MATERIALS AND METHODS: T1-weighted MR images of 52 glioblastoma patients with unilateral tumours acquired before and three months after the end of radio(chemo)therapy were analysed. GM and WM volumes in the contralateral hemisphere were compared between segmenting the whole brain (full) and the contralateral hemisphere only (cl) with SPM and FSL. Relative GM and WM volumes were compared using paired t tests and correlated with the corresponding mean dose in GM and WM, respectively. RESULTS: Mean GM atrophy was significantly higher for full segmentation compared to cl segmentation when using SPM (mean ± std: ΔV(GM,full) = − 3.1% ± 3.7%, ΔV(GM,cl) = − 1.6% ± 2.7%; p < 0.001, d = 0.62). GM atrophy was significantly correlated with the mean GM dose with the SPM cl segmentation (r = − 0.4, p = 0.004), FSL full segmentation (r = − 0.4, p = 0.004) and FSL cl segmentation (r = -0.35, p = 0.012) but not with the SPM full segmentation (r = − 0.23, p = 0.1). CONCLUSIONS: For accurate normal tissue volume measurements in brain tumour patients using SPM, abnormal tissue needs to be masked prior to segmentation, however, this is not necessary when using FSL. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10334-021-00922-3.
format Online
Article
Text
id pubmed-8901471
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-89014712022-03-15 Overestimation of grey matter atrophy in glioblastoma patients following radio(chemo)therapy Gommlich, A. Raschke, F. Petr, J. Seidlitz, A. Jentsch, C. Platzek, I. van den Hoff, J. Kotzerke, J. Beuthien-Baumann, B. Baumann, M. Krause, M. Troost, E. G. C. MAGMA Research Article OBJECTIVE: Brain atrophy has the potential to become a biomarker for severity of radiation-induced side-effects. Particularly brain tumour patients can show great MRI signal changes over time caused by e.g. oedema, tumour progress or necrosis. The goal of this study was to investigate if such changes affect the segmentation accuracy of normal appearing brain and thus influence longitudinal volumetric measurements. MATERIALS AND METHODS: T1-weighted MR images of 52 glioblastoma patients with unilateral tumours acquired before and three months after the end of radio(chemo)therapy were analysed. GM and WM volumes in the contralateral hemisphere were compared between segmenting the whole brain (full) and the contralateral hemisphere only (cl) with SPM and FSL. Relative GM and WM volumes were compared using paired t tests and correlated with the corresponding mean dose in GM and WM, respectively. RESULTS: Mean GM atrophy was significantly higher for full segmentation compared to cl segmentation when using SPM (mean ± std: ΔV(GM,full) = − 3.1% ± 3.7%, ΔV(GM,cl) = − 1.6% ± 2.7%; p < 0.001, d = 0.62). GM atrophy was significantly correlated with the mean GM dose with the SPM cl segmentation (r = − 0.4, p = 0.004), FSL full segmentation (r = − 0.4, p = 0.004) and FSL cl segmentation (r = -0.35, p = 0.012) but not with the SPM full segmentation (r = − 0.23, p = 0.1). CONCLUSIONS: For accurate normal tissue volume measurements in brain tumour patients using SPM, abnormal tissue needs to be masked prior to segmentation, however, this is not necessary when using FSL. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10334-021-00922-3. Springer International Publishing 2021-03-31 2022 /pmc/articles/PMC8901471/ /pubmed/33786695 http://dx.doi.org/10.1007/s10334-021-00922-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Article
Gommlich, A.
Raschke, F.
Petr, J.
Seidlitz, A.
Jentsch, C.
Platzek, I.
van den Hoff, J.
Kotzerke, J.
Beuthien-Baumann, B.
Baumann, M.
Krause, M.
Troost, E. G. C.
Overestimation of grey matter atrophy in glioblastoma patients following radio(chemo)therapy
title Overestimation of grey matter atrophy in glioblastoma patients following radio(chemo)therapy
title_full Overestimation of grey matter atrophy in glioblastoma patients following radio(chemo)therapy
title_fullStr Overestimation of grey matter atrophy in glioblastoma patients following radio(chemo)therapy
title_full_unstemmed Overestimation of grey matter atrophy in glioblastoma patients following radio(chemo)therapy
title_short Overestimation of grey matter atrophy in glioblastoma patients following radio(chemo)therapy
title_sort overestimation of grey matter atrophy in glioblastoma patients following radio(chemo)therapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8901471/
https://www.ncbi.nlm.nih.gov/pubmed/33786695
http://dx.doi.org/10.1007/s10334-021-00922-3
work_keys_str_mv AT gommlicha overestimationofgreymatteratrophyinglioblastomapatientsfollowingradiochemotherapy
AT raschkef overestimationofgreymatteratrophyinglioblastomapatientsfollowingradiochemotherapy
AT petrj overestimationofgreymatteratrophyinglioblastomapatientsfollowingradiochemotherapy
AT seidlitza overestimationofgreymatteratrophyinglioblastomapatientsfollowingradiochemotherapy
AT jentschc overestimationofgreymatteratrophyinglioblastomapatientsfollowingradiochemotherapy
AT platzeki overestimationofgreymatteratrophyinglioblastomapatientsfollowingradiochemotherapy
AT vandenhoffj overestimationofgreymatteratrophyinglioblastomapatientsfollowingradiochemotherapy
AT kotzerkej overestimationofgreymatteratrophyinglioblastomapatientsfollowingradiochemotherapy
AT beuthienbaumannb overestimationofgreymatteratrophyinglioblastomapatientsfollowingradiochemotherapy
AT baumannm overestimationofgreymatteratrophyinglioblastomapatientsfollowingradiochemotherapy
AT krausem overestimationofgreymatteratrophyinglioblastomapatientsfollowingradiochemotherapy
AT troostegc overestimationofgreymatteratrophyinglioblastomapatientsfollowingradiochemotherapy